Clinical Implication of the Antidiuretic Hormone (ADH) Receptor Antagonist Mozavaptan Hydrochloride in Patients with Ectopic ADH Syndrome [PDF]
Japanese Journal of Clinical Oncology, 2010 Ectopic antidiuretic hormone syndrome is a medical emergency characterized by dilutional hyponatremia. Clinical effectiveness of the vasopressin V2 receptor antagonist mozavaptan was evaluated in 16 patients. In short-term (7-day) treatment with the drug, serum sodium concentration (mean ± standard deviation) significantly (P = 0.002) increased from ...
Kiyoshi Mori +9 more
openaire +4 more sources
Successful Long-Term Treatment of Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion with Satavaptan (SR121463B), an Orally Active Nonpeptide Vasopressin V2-Receptor Antagonist [PDF]
Clinical Journal of the American Society of Nephrology, 2006 The effects of satavaptan (SR121463B), a novel long-acting orally active vasopressin V(2)-receptor antagonist, were investigated in patients with the syndrome of inappropriate antidiuretic hormone secretion (SIADH). In the first part of this randomized, double-blind study, 34 patients first were treated with satavaptan (versus placebo) for up to 5 d ...
Hassan M. Heshmati +6 more
openaire +4 more sources
Endocrine Journal, 2012 Hyponatraemia (serum sodium ...
Rajendran, R, Grossman, AB, Kar, P
openaire +5 more sources
Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD [PDF]
Frontiers in Endocrinology, 2023 BackgroundSyndrome of inappropriate antidiuresis (SIAD) is one of the most frequent causes of euvolemic hyponatremia (serum sodium levels < 135 mEq/L) and it represents more than 35% of hyponatremia cases in hospitalized patients.
Anna Arecco +9 more
doaj +2 more sources
Biological and Pharmaceutical Bulletin, 2007 We investigated the effects of intravenous administration of conivaptan hydrochloride, a dual vasopressin V1A and V2 receptor antagonist, on blood electrolytes and plasma osmolality in rats with an experimental syndrome of inappropriate secretion of antidiuretic hormone (SIADH).
Masao Sasamata +6 more
openaire +5 more sources
Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database [PDF]
Scientific ReportsBackground NK-1 receptor antagonists (NK-1RAs) are proven to be successful in preventing chemotherapy-induced nausea and vomiting (CINV). The safety profile of NK-1RAs has not been systematically analyzed in the real world.
Hong Pan +4 more
doaj +2 more sources
Vasopressin and a Nonpeptide Antidiuretic Hormone Receptor Antagonist (OPC-31260)
Blood Pressure, 1994 The development of nonpeptide orally active AVP analogues has provided a new tool with which to assess the physiological and pathophysiological role of vasopressin (AVP). We have previously characterised the nonpeptide vasopressin V1 receptor antagonist OPC-21268, and now report the in vitro characterisation of the nonpeptide V2 receptor antagonist OPC-
J Stephenson +4 more
openaire +4 more sources
Vasopressin-2 receptor antagonists: potent but potentially dangerous drugs for the treatment of severe hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion [PDF]
Endocrine Abstracts, 2015 Vikki Tilliridou +2 more
openaire +3 more sources
Metabolic effects of vasopressin in pathophysiology of diabetic kidney disease
Frontiers in Endocrinology, 2023 The diabetic kidney disease (DKD) is the major cause of the chronic kidney disease (CKD). Enhanced plasma vasopressin (VP) levels have been associated with the pathophysiology of DKD and CKD.
Svetlana Lebedeva +7 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 In addition to long-term regulation of blood pressure (BP), in the kidney resides the initial trigger for hypertension development due to an altered capacity to excrete sodium and water.
Ignazio Verzicco +17 more
doaj +1 more source